Vr Adviser, LLC Savara Inc Transaction History

Vr Adviser, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$3.18 - $4.9 $11.7 Million - $18.1 Million	-3,684,865 Reduced 51.29%	3,500,000 $16.5 Million
Q3 2023 Nov 14, 2023	BUY	$2.97 - $3.88 $2.48 Million - $3.23 Million	833,334 Added 13.12%	7,184,865 $27.2 Million
Q4 2022 May 15, 2023	BUY	$1.11 - $1.64 $1.99 Million - $2.95 Million	1,796,493 Added 39.44%	6,351,531 $9.84 Million
Q4 2022 Feb 14, 2023	BUY	$1.11 - $1.64 $1.99 Million - $2.95 Million	1,796,493 Added 39.44%	6,351,531 $9.84 Million
Q3 2022 May 15, 2023	BUY	$1.36 - $1.88 $595,010 - $822,515	437,508 Added 10.63%	4,555,038 $6.47 Million
Q3 2022 Nov 14, 2022	BUY	$1.36 - $1.88 $595,010 - $822,515	437,508 Added 10.63%	4,555,038 $7.06 Million
Q2 2022 May 15, 2023	SELL	$1.1 - $1.58 $2.46 Million - $3.53 Million	-2,234,001 Reduced 35.17%	4,117,530 $6.26 Million
Q2 2022 Aug 15, 2022	BUY	$1.1 - $1.58 $2.43 Million - $3.5 Million	2,212,265 Added 116.11%	4,117,530 $6.26 Million
Q1 2022 May 16, 2022	BUY	$1.05 - $1.36 $2 Million - $2.59 Million	1,905,265 New	1,905,265 $2.5 Million

129

158M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $369M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Vr Adviser, LLC, based on Form 13F filings with the SEC.

Stay updated on Vr Adviser, LLC with notifications on news.